Immunimed Inc, a clinical stage Biopharmaceutical company, with an ongoing phase 2 clinical trial of the World’s First oral antibody TREATMENT for C Diff.
This is my somewhat unconventional Pitch Deck for the World’s First oral antibody PREVENTIVE treatment against C Diff.
Interestingly, this is how we registered our first animal health treatment, with the claim “to aid in the prevention of diarrhea caused by E Coli bacteria infection”. So we have already proven the efficacy of our therapeutic antibodies being used to prevent the same infection.
What the Hell is C Diff?
This is the question you’re probably asking your doctor when he’s giving you that diagnosis. And if you’re lucky you’ve only got debilitating cramps and multiple occurrences of explosive diarrhea. Or if not so lucky you’re in for many months of relapse infections and even worse, death in about 6% of cases, even to the point of quick onset death in fulminant cases. And if you’re over 65, in the hospital with multiple comorbidities, there is a higher expectancy of death within 30 days.
So why doesn’t anyone outside of healthcare know about C Diff? This is crazy as it kills the same number of people every year as prostate cancer, and I know you’ve heard of prostate cancer. Also C Difficile infection is the number one hospital acquired disease in America, where each new case costs the system an extra $25k, totaling in excess of $5B annually. And herein lies the problem.
The answer is: It’s complicated! To the healthcare industry, C Diff is definitely bad for the patient but generates extra revenue for the system. And until it can generate more revenue to the system than it costs, it will stay below the radar. That is, until there is a preventive solution that will generate revenue to the system that is greater than what the infection now generates, there’s no incentive to let the public in on it.
Our new “C Diff Control” will make C Diff financially relevant, disincentivizing the system to keep patients in the dark about it. But best of all and the real reason we should be in this business, patient suffering from this miserable disease will become a thing of the past.
A win/win solution and why you should participate.
Our Expertise
Proving the efficacy of IgY antibodies in the lab and animal models is one thing. Taking this to a commercial level including manipulating thousands of individual immune systems and then processing the results into safe and effective patient doses has taken many years to perfect.
01. Vaccine Development
To date we have successfully researched and developed more than ten different vaccines to produce antibodies for both human and animal health treatments..
02. Clinical Development / Animal
We registered the World’s first oral antibody animal health Veterinary Biologic treatment in 2007, with the claim; “To aid in the prevention’s of diarrhea caused by E Coli bacteria in newly weaned piglets.”
03. Clinical Development / Human
Ongoing Health Canada sanctioned phase 2 clinical trial of oral antibodies to treat C Difficile infection in humans over 18 years of age.